(February 13, 2019) Data from a study conducted by researchers at MD Anderson and Johns Hopkins suggest that an adjuvant gastrointestinal (GI)-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous ovarian cancer. Because mucinous patients don’t typically do particularly well on regimens usually used to treat the more common … Continued
Our menu is heating up! Here’s what you can enjoy at Turn Up the Heat DC on March 5th. For one night only, treat yourself to all the foodie delights that DC’s most talented female chefs, mixologists and restaurateurs have to offer, including: And so much more! Check out our ever-expanding lineup of female culinary superstars bringing … Continued
OCRA is pleased to announce we have earned our NINTH consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This is the highest rating awarded by Charity Navigator, and demonstrates our steady commitment to responsible fiscal management, organizational transparency, and accountability, as we continue to strive toward cures for ovarian cancer. A 4-star … Continued
February 4th is World Cancer Day. Today, millions of people across the globe raise a collective voice for progress. Against cancer in its many insidious forms, and for access to treatments and care for those who need it, no matter where they live. As the leading organization in the world fighting ovarian cancer from all … Continued
(January 23, 2019) Researchers at Massachusetts General Hospital recently found a correlation between a class of drug used to treat hypertension and longer survival rates in ovarian cancer patients when used with paclitaxel, a drug used to treat ovarian cancer. The antihypertension drug used in a phase II clinical trial, losartan, aids the body in … Continued
Another reason you don’t want to miss OCRA’s Turn Up the Heat! Not only does the event feature fabulous tastings from DC’s female culinary stars—we are thrilled to announce that the amazing Chef Elle Simone, from PBS’ America’s Test Kitchen will be our host! Elle Simone Scott began dazzling the culinary world in 2003, and … Continued
(January 10, 2019) We’re pleased to announce OCRA’s newest research grants of $5.25 million to 23 top scientists at 14 top medical centers. In 2019, with our other ongoing grants and programs, OCRA is investing nearly $9 million in our fight against ovarian cancer. “OCRA invests in medical research to cure ovarian cancer. Scientists need … Continued
OCRA’s Turn Up the Heat is coming March 5th! Get your tickets now and treat yourself to our fabulous foodie fest, packed full of tantalizing treats and eats from the DC area’s most exciting female chefs, mixologists and restaurateurs, all for a good cause. We’re excited to announce that this year’s event will be hosted … Continued
Join our donors in supporting OCRA and your gift will have double the impact in the fight against ovarian cancer. Thanks to a generous year-end pledge from angel patrons and investment income to cover fundraising and administrative expenses, 100% of your gift will directly support OCRA’s research, education, patient support and advocacy programs. AND your … Continued
(December 21, 2018) This month, researchers in Boston published their findings on how PARP inhibitors (PARPi) cause a chain reaction of responses from the tumor and its environment. Study authors, including OCRA grantee Ursula Matulonis, MD, treated BRCA-1 deficient tumors with olaparib, a PARPi, and found that it began both a natural and medically induced … Continued
(December 20, 2018) Earlier this year a phase III clinical trial, known as SOLO-1, showed that frontline olaparib (Lynparza) can reduce the risk of disease progression or death by up to 70% in women with BRCA 1 or 2 positive, advanced stage epithelial ovarian, fallopian tube, and primary peritoneal cancers. Those included in the study … Continued
(December 7, 2018) A study published last month analyzed two clinical trials that sought to determine the best first step for advanced tubo-ovarian cancers, neoadjuvant chemotherapy or debulking surgery. The two studies, EORTC and CHORUS, had a total of 1,220 participants whose median age was 63 years. Both studies included stage IIIC and stage IV … Continued
Get email updates about research news, action alerts, and ways to join the fight.
